Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

Clogged Artery

Biotech

After 21-year journey, Esperion to test market for a cholesterol pill that is less expensive than some competitors

By Matthew Herper

Cervical cancer cells

Biotech

Antigen-based metric could better predict which patients benefit from immunotherapy, study says

By Shafaq Zia

advertisement

office cubicles

Biotech

In a cramped Kendall Square, biotech startups sublet desks and squeeze into shared labs

By Kate Sheridan

advertisement

Three vials

Pharma

Roche confirms departure of gene therapy pioneer Kathy High

By Matthew Herper

colored DNA sequencing

Health Tech

FDA names genes that may interact with specific drugs, offering clarity to genetic testing industry

By Rebecca Robbins

Frank Reynolds, CEO of PixarBio, sentenced to 7 years for defrauding investors

Biotech

Biotech founder who said his painkiller would replace opioids sentenced to 7 years in prison

By Jonathan Saltzman — Boston Globe

Amarin Transcript

Adam's Take

‘Pharma doesn’t like fish oil’: Wall Street funds sold Amarin after big win with heart drug

By Adam Feuerstein

advertisement

Biotech

Microbiome-based drug makers are hoping new late-stage data will pull the field out of the shadows

By Kate Sheridan

advertisement

NASDAQ

Biotech

A longtime health care investor recalls the insulin bong, praises discipline in valuations, and looks to South America

By Adam Feuerstein, Damian Garde, and Rebecca Robbins

Biotech

Weight-loss drug to be pulled from market after FDA expresses concerns on cancer risk

By Adam Feuerstein

China virus statue

Biotech

U.S. biotechs fear the coronavirus outbreak will delay their China-based research

By Kate Sheridan

ProstateCancerCell

Biotech

With new combination drug data, Exelixis takes another shot at prostate cancer treatment

By Adam Feuerstein

Biogen Cambridge

Biotech

Two more failed Alzheimer’s drugs sharpen focus on Biogen’s chances for aducanumab

By Damian Garde

Daniel O'Day STAT Summit

Adam's Take

Investor impatience with Gilead reclamation project sparks acquisition chatter

By Adam Feuerstein

DNA Editing

Biotech

Beam Therapeutics raises $180 million in IPO

By Jonathan Saltzman — Boston Globe

Jeff Bluestone

Biotech

Jeffrey Bluestone steps down as Parker Institute president to develop cell therapies for autoimmune diseases

By Matthew Herper

Sanofi

Biotech

Sanofi reports positive results on multiple sclerosis drug licensed from Principia

By Matthew Herper

Biotech

Biogen wins patent challenge to key multiple sclerosis drug

By Adam Feuerstein

Pink brain

Biotech

This biotech just bought three failed drugs. Here’s why

By Kate Sheridan

Regeneron

Health

In the race to develop a coronavirus treatment, Regeneron thinks it has the inside track

By Damian Garde

Exclusive

This VC firm once pledged to never invest in health care. Now it’s launching its third life sciences fund

By Erin Brodwin

Biotech Mt Rushmore

Adam's Take

If biotech had a Mount Rushmore, whose heads would you chisel in the granite?

By Adam Feuerstein

Peanut allergy treatment

Biotech

FDA approves the first treatment for peanut allergy, but commercial success is hardly assured

By Adam Feuerstein

Daniel O'Day STAT Summit

STAT Summit

Watch: CEO Daniel O’Day says Gilead is in a ‘sweet spot.’ What’s next?

By STAT staff

Biotech

European regulators could take a harder line on the review of an Agios blood cancer drug

By Adam Feuerstein

Adam's Take

As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking

By Adam Feuerstein

Hepatitis C virus model

Biotech

Spring Bank scraps hepatitis R&D after patient dies in trial

By Jonathan Saltzman — Boston Globe

Steven Holtzman

Biotech

In a pivot, Decibel Therapeutics loses its founding CEO — and some of its discovery programs

By Kate Sheridan

Missing women

Biotech

Three star scientists announce plan to solve biotech’s ‘missing women’ problem

By Sharon Begley